Dr. Wu on Efficacy of Approved Agents in Colorectal Cancer

Jennifer Wu, MD
Published: Wednesday, Nov 04, 2015



Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the efficacy of regorafenib and TAS-102 for the treatment of patients with colorectal cancer (CRC).

As a single agent, regorafenib has been shown to have an overall survival (OS) benefit in refractory patients with CRC. A second oral agent, TAS-102, has had an OS benefit in patients. Wu explains that patients who receive TAS-102 were pretreated with regorafenib. 

These agents are chosen based on patient preference and prior patient experience. Sometimes, the drugs can be administered sequentially, Wu says.

<<< View more from the 2015 CFS Annual Meeting



Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the efficacy of regorafenib and TAS-102 for the treatment of patients with colorectal cancer (CRC).

As a single agent, regorafenib has been shown to have an overall survival (OS) benefit in refractory patients with CRC. A second oral agent, TAS-102, has had an OS benefit in patients. Wu explains that patients who receive TAS-102 were pretreated with regorafenib. 

These agents are chosen based on patient preference and prior patient experience. Sometimes, the drugs can be administered sequentially, Wu says.

<<< View more from the 2015 CFS Annual Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x